0001179706-15-000302.txt : 20151112 0001179706-15-000302.hdr.sgml : 20151112 20151112183250 ACCESSION NUMBER: 0001179706-15-000302 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20151101 FILED AS OF DATE: 20151112 DATE AS OF CHANGE: 20151112 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HP INC CENTRAL INDEX KEY: 0000047217 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER & OFFICE EQUIPMENT [3570] IRS NUMBER: 941081436 STATE OF INCORPORATION: DE FISCAL YEAR END: 1031 BUSINESS ADDRESS: STREET 1: 1501 PAGE MILL ROAD STREET 2: BLDG 5M, MS 1560 CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 6502368152 MAIL ADDRESS: STREET 1: 1501 PAGE MILL ROAD STREET 2: BLDG 5M, MS 1560 CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: HEWLETT PACKARD CO DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FLAXMAN JON E CENTRAL INDEX KEY: 0001207617 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-04423 FILM NUMBER: 151226337 MAIL ADDRESS: STREET 1: C/O HEWLETT-PACKARD CO STREET 2: 3000 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 3 1 edgar.xml PRIMARY DOCUMENT X0206 3 2015-11-01 0 0000047217 HP INC HPQ 0001207617 FLAXMAN JON E C/O HP INC. 1501 PAGE MILL ROAD PALO ALTO CA 94304 0 1 0 0 Chief Operating Officer Common Stock 0 D Employee Stock Option (right to buy) 13.83 2013-12-06 2020-12-06 Common Stock 20000 D Employee Stock Option (right to buy) 26.99 2014-12-11 2021-12-11 Common Stock 17000 D Employee Stock Option (right to buy) 37.36 2015-09-17 2022-12-10 Common Stock 23100 D Employee Stock Option (right to buy) 26.96 2016-10-30 2023-10-30 Common Stock 217822 D Restricted Stock Units Common Stock 7116.2792 D Restricted Stock Units Common Stock 5894.0882 D Restricted Stock Units Common Stock 7863.1693 D Restricted Stock Units Common Stock 22952.286 D Restricted Stock Units Common Stock 64911 D This option became exercisable beginning on this date. The performance contingent stock options will vest 33.3% on each of the first two anniversaries of the grant date, and 33.4% on the third anniversary, in each case subject to the satisfaction of certain stock price performance conditions being met within five years following the grant date. This option is no longer exercisable beginning on this date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. On 12/06/12 the reporting person was granted 20,000 restricted stock units ("RSUs"), 6,666 of which vested on 12/06/13, 6,667 of which vested on 12/06/14, and 6,667 of which will vest on 12/06/15. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on the Issuer's common stock. The number of derivative securities in column 5 includes 449.2792 vested dividend equivalent rights accrued but not released since the grant date. On 12/11/13 the reporting person was granted 8,500 RSUs, 2,833 of which vested on 12/11/14, 2,833 of which will vest on 12/11/15, and 2,834 of which will vest on 12/11/16. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on the Issuer's common stock. The number of derivative securities in column 5 includes 227.0882 vested dividend equivalent rights accrued but not released since the grant date. On 12/10/14 the reporting person was granted 7,700 RSUs, 2,566 of which will vest on 12/10/15, and 2,567 of which will vest on each of 12/10/16 and 12/10/17. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on the Issuer's common stock. The number of derivative securities in column 5 includes 163.1693 vested dividend equivalent rights accrued but not released since the grant date. On 04/27/15 the reporting person was granted 22,679 RSUs, 7,559 of which will vest on 04/27/16, and 7,560 of which will vest on each of 04/27/17 and 04/27/18. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on the Issuer's common stock. The number of derivative securities in column 5 includes 273.286 vested dividend equivalent rights accrued but not released since the grant date. On 10/30/15 the reporting person was granted 64,911 RSUs, 21,637 of which will vest on each of 10/30/16, 10/30/17, and 10/30/18. Dividend equivalent rights accrue with respect to these RSUs when and as dividends are paid on the Issuer's common stock. Katie Colendich as Attorney-in-Fact for Jon Flaxman 2015-11-12 EX-24 2 flaxmanpoa110115.htm ORIGINAL POA ON FILE WITH ISSUER EDS senior management has for some time been subject to certain guidelines as to the timing of trades in company securities. These guidelines were established to protect the interests of EDS and to help individual officers avoid inadvertent violations of

Exhibit 24

 

POWER OF ATTORNEY

 

            Know all by these presents that the undersigned hereby constitutes and appoints Ruairidh Ross, Katie Colendich and David Deitchman, and each of them, signing singly, his true and lawful attorney-in-fact to:

 

 

(1)

execute for and on behalf of the undersigned, in the undersigned's capacity as an executive officer or director of HP Inc. ("HP"), any Forms 3, 4 and 5 or  any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder;
 
 

(2)

do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete the execution of any such Forms 3, 4 or 5 and any amendments thereto and the timely filing of such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
 
 

(3)

take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion.

 

            The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as such attorney-in-fact might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is HP assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

 

            This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by HP, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

            The undersigned understands and acknowledges that the Securities and Exchange Commission requires any electronic requests for a Form ID and/or Passphrase be authenticated. The undersigned hereby confirms the authenticity of any such electronic request submitted for a Form ID and/or Passphrase, or any update thereto, by any of the foregoing attorneys-in-fact on or after the date hereof.

 

            IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of October, 2015.

 

 

                                                                                                                           /S/ JON FLAXMAN                                              

                                                                                                                          Jon Flaxman